A new drug-delivery system can be built on a genuinely novel chemical — or on materials the world already knows. The second route is slower to sound exciting and far faster to de-risk. Here is why, and where the honest limits are.
What “GRAS” actually means
GRAS — Generally Recognised As Safe — is a United States FDA concept. It attaches to a substance for a specified use and at a specified level, established either by long use in food or by scientific procedures, and it can be the subject of an FDA GRAS notification. Two things follow that are easy to miss. First, GRAS is, in origin, a food concept — it is not a pharmaceutical approval. Second, it is bounded: a material that is GRAS for one use and level is not automatically cleared for another. The EU and UK do not use the term at all; there, the equivalent reassurance comes from food-additive status, pharmacopoeial monographs and a record of prior use.
Why established materials lower the regulatory burden
When a delivery system depends on a brand-new synthetic enhancer, someone has to build that molecule’s safety case from the ground up — the full novel-excipient package. When it depends instead on a material with an established safety pedigree — food and pharmaceutical history, and, in the US, GRAS food status — much of that burden can be discharged by reference rather than rebuilt, subject to confirming precedent at the proposed pharmaceutical route and level. The pharmaceutical question is answered not by GRAS itself but by the record of prior use in approved drug products — in the US, the FDA’s Inactive Ingredient Database — and, where a use exceeds that precedent, by a focused safety justification for the gap.
The honest limit
Established does not mean exempt. A novel route, a higher level or a new combination can still trigger a safety requirement, and a food pedigree carries no automatic weight with the MHRA or EMA. The credible claim is narrower, and stronger, than a blanket one: established materials reduce the novel-excipient burden relative to a genuinely novel enhancer — they do not remove it where the pharmaceutical use is itself new.
Where Ibumix sits
Ibumix builds its liquid drug-delivery platforms on glyceryl caprate/caprylate (GCC), a medium-chain glyceride with an established safety pedigree — including GRAS food status in the US and a history of use in food and pharmaceutical products. The intent is to lower the novel-excipient safety burden relative to a bespoke synthetic enhancer, subject to confirming precedent at the proposed route and level. The platform is at proof-of-concept stage and is being developed toward a defined regulatory pathway with a future partner; it is not an approved product, and “GRAS” is used here to describe the materials’ established status, not to claim regulatory approval. Against the medium-chain enhancer field — sodium caprate (C10) and the synthetic enhancer SNAC used in oral semaglutide — Ibumix differentiates on its formulation approach and small-molecule focus, not on a blanket safety claim.
Established materials do not make the regulatory work disappear. They point the same scarce effort at the questions that actually remain.
Read deeper
- Bioavailability: the medicine that never arrives — the problem these materials are chosen to solve.
- Lipid and liquid-crystal drug delivery — the chemistry the safety story rests on.
- Engineering the Next Generation of Pharmaceutical Excipients — why the excipient decides so much of the outcome.
About Ibumix
Ibumix is developing a series of new liquid drug-delivery platforms built on glyceryl caprate (GCC) lipid chemistry — re-engineering how established medicines are delivered, beginning with the NSAID class. Ibuprofen and naproxen are the starting points; the opportunity extends well beyond them.
Sources
- US FDA GRAS programme — Federal Food, Drug, and Cosmetic Act; FDA CFSAN GRAS notifications.
- FDA Inactive Ingredient Database (precedent of excipient use in approved drug products).
- FDA Guidance for Industry — Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients (2005).
- EMA Guideline on excipients in the dossier for application for marketing authorisation (EMA/CHMP/QWP/396951/2006; current revision).
See how this connects to what Ibumix is building: the Mix platform — one architecture, seven chassis.